Alnylam Pharmaceuticals, Inc.

ALNY trades at a 68.4 P/E—nearly triple the pharmaceutical sector median—despite an RSI of 38.7 suggesting mild oversold conditions. The $43B market cap reflects premium valuation for a specialty biotech, but the disconnect between elevated multiples and subdued momentum metrics is noteworthy. The stock sits below its 52-week high, creating a setup where value and technicals don't align: either the market is pricing in extraordinary future growth that hasn't materialized yet, or the valuation compression hasn't caught up with momentum weakness. This tension warrants scrutiny before conviction either direction.